Leslie Chong is leaving after almost 11 years leading Imugene, while the company also reported another partial response in Azer-cel.
Why it mattersLeadership changes at a small biotech can affect strategy, funding signals and investor sentiment.
Free. Start reading in seconds, no signup needed.
Get the free app, read the whole feed
InSnip is the day's best stories, source-backed and read in under a minute. Get your free daily drop and never miss what matters.